Lorraine E Levitt Katz1, Fida Bacha2, Samuel S Gidding3, Ruth S Weinstock4, Laure El Ghormli5, Ingrid Libman6, Kristen J Nadeau7, Kristin Porter6, Santica Marcovina8. 1. Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Texas Children's Hospital, Baylor College of Medicine, Houston, TX. 3. Nemours Cardiac Center, Alfred I. DuPont Hospital for Children, Wilmington, DE. 4. SUNY Upstate Medical University, Department of Medicine, Syracuse, NY. 5. George Washington University Biostatistics Center, Rockville, MD. Electronic address: elghorml@bsc.gwu.edu. 6. Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA. 7. University of Colorado Anschutz Medical Campus, Aurora, CO. 8. Northwest Lipid Research Laboratories, University of Washington, Seattle, WA.
Abstract
OBJECTIVES: Data regarding atherogenic dyslipidemia and the inflammation profile in youth with type 2 diabetes is limited and the effect of insulin therapy on these variables has not previously been studied in youth. We determined the impact of insulin therapy on lipid and inflammatory markers in youth with poorly controlled type 2 diabetes. STUDY DESIGN: In the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) multicenter trial, 285 participants failed to sustain glycemic control on randomized treatment (primary outcome, glycated hemoglobin A1c [HbA1c] at ≥8% for 6 months); 363 maintained glycemic control (never reached primary outcome). Statins were used for a low-density lipoprotein cholesterol of ≥130 mg/dL. Upon reaching the primary outcome, insulin was started. Changes in lipids and inflammatory markers (slopes over time) were examined. RESULTS:Progression of dyslipidemia was related to glycemic control. In those with the primary outcome, insulin therapy impacted HbA1c modestly, and dampened the increase in total cholesterol, low-density lipoprotein cholesterol, and total apolipoprotein B, although statin use increased from 8.6% to 22% year after the primary outcome. The increase in triglycerides and plasma nonesterified fatty acids stabilized after insulin was started, independent of HbA1c. There was an increase in high-sensitivity C-reactive protein that continued after insulin initiation, related to HbA1c and percent overweight. CONCLUSIONS: Worsening dyslipidemia and inflammation over time raise concern regarding premature development of atherosclerosis in youth with type 2 diabetes. Insulin therapy has a limited benefit in the absence of glycemic control. Strategies to achieve better glycemic control are needed. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00081328.
RCT Entities:
OBJECTIVES: Data regarding atherogenic dyslipidemia and the inflammation profile in youth with type 2 diabetes is limited and the effect of insulin therapy on these variables has not previously been studied in youth. We determined the impact of insulin therapy on lipid and inflammatory markers in youth with poorly controlled type 2 diabetes. STUDY DESIGN: In the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) multicenter trial, 285 participants failed to sustain glycemic control on randomized treatment (primary outcome, glycated hemoglobin A1c [HbA1c] at ≥8% for 6 months); 363 maintained glycemic control (never reached primary outcome). Statins were used for a low-density lipoprotein cholesterol of ≥130 mg/dL. Upon reaching the primary outcome, insulin was started. Changes in lipids and inflammatory markers (slopes over time) were examined. RESULTS: Progression of dyslipidemia was related to glycemic control. In those with the primary outcome, insulin therapy impacted HbA1c modestly, and dampened the increase in total cholesterol, low-density lipoprotein cholesterol, and total apolipoprotein B, although statin use increased from 8.6% to 22% year after the primary outcome. The increase in triglycerides and plasma nonesterified fatty acids stabilized after insulin was started, independent of HbA1c. There was an increase in high-sensitivity C-reactive protein that continued after insulin initiation, related to HbA1c and percent overweight. CONCLUSIONS: Worsening dyslipidemia and inflammation over time raise concern regarding premature development of atherosclerosis in youth with type 2 diabetes. Insulin therapy has a limited benefit in the absence of glycemic control. Strategies to achieve better glycemic control are needed. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00081328.
Authors: A A Rivellese; L Patti; G Romano; F Innelli; L Di Marino; G Annuzzi; M Iavicoli; G A Coronel; G Riccardi Journal: J Clin Endocrinol Metab Date: 2000-11 Impact factor: 5.958
Authors: Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert Journal: N Engl J Med Date: 2008-06-06 Impact factor: 91.245
Authors: H Yki-Järvinen; R Kauppinen-Mäkelin; M Tiikkainen; M Vähätalo; H Virtamo; K Nikkilä; T Tulokas; S Hulme; K Hardy; S McNulty; J Hänninen; H Levänen; S Lahdenperä; R Lehtonen; L Ryysy Journal: Diabetologia Date: 2006-02-03 Impact factor: 10.122
Authors: Najib Lamharzi; Catherine B Renard; Farah Kramer; Subramaniam Pennathur; Jay W Heinecke; Alan Chait; Karin E Bornfeldt Journal: Diabetes Date: 2004-12 Impact factor: 9.461
Authors: Jeanie B Tryggestad; Rachana D Shah; Barbara H Braffett; Fida Bacha; Samuel S Gidding; Rose A Gubitosi-Klug; Amy S Shah; Elaine M Urbina; Lorraine E Levitt Katz Journal: Pediatr Diabetes Date: 2020-07-02 Impact factor: 4.866
Authors: Fida Bacha; Laure El Ghormli; Silva Arslanian; Philip Zeitler; Lori M Laffel; Lorraine E Levitt Katz; Rachelle Gandica; Nancy T Chang; Jennifer E Sprague; Sarah A Macleish Journal: Pediatr Diabetes Date: 2019-08-27 Impact factor: 4.866
Authors: EunSeok Cha; Francisco J Pasquel; Fengxia Yan; David R Jacobs; Sandra B Dunbar; Guillermo Umpierrez; Yuni Choi; James M Shikany; Michael P Bancks; Jared P Reis; Melissa Spezia Faulkner Journal: Diabetes Res Clin Pract Date: 2021-11-11 Impact factor: 5.602
Authors: Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Kathryn A Williams; R Paul Wadwa; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; Amy S Shah; Clary B Clish; Sudha B Biddinger Journal: Pediatr Diabetes Date: 2020-09-15 Impact factor: 4.866
Authors: Amy S Shah; Kristen J Nadeau; Michael A Helmrath; Thomas H Inge; Stavra A Xanthakos; Megan M Kelsey Journal: Semin Pediatr Surg Date: 2020-01-25 Impact factor: 2.754
Authors: Mary Ellen Vajravelu; Talia A Hitt; Sandra Amaral; Lorraine E Levitt Katz; Joyce M Lee; Andrea Kelly Journal: Pediatr Diabetes Date: 2021-06-30 Impact factor: 3.409
Authors: Ryan P Brady; Amy S Shah; Elizabeth T Jensen; Jeanette M Stafford; Ralph B D'Agostino; Lawrence M Dolan; Lisa Knight; Giuseppina Imperatore; Christine B Turley; Angela D Liese; Elaine M Urbina; Jean M Lawrence; Catherine Pihoker; Santica Marcovina; Dana Dabelea Journal: Pediatr Diabetes Date: 2021-08-15 Impact factor: 4.866